OncoMatch/Clinical Trials/NCT05896046

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Is NCT05896046 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including SHR2554+ SHR1701 and SHR-1701 for relapsed or refractory hodgkin lymphoma.

Phase 1/2RecruitingChinese PLA General HospitalNCT05896046Data as of May 2026

Treatment: SHR2554+ SHR1701 · SHR-1701 — This is an open-label, phase I/II dose escalation and expansion trial. The primary objective of dose escalation phase I study is to evaluate the safety and feasibility of SHR1701 in patients with relapsed or refractory classical Hodgkin Lymphoma. The primary objective of open-label, randomized, phase II study is to assess the antitumor effect of SHR1701 alone or in combination with SHR2554 in patients with relapsed or refractory classical Hodgkin Lymphoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hodgkin Lymphoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 2 prior lines

Lab requirements

Blood counts

adequate marrow function

Kidney function

adequate renal function

Liver function

adequate liver function

Cardiac function

adequate heart function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify